Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Vitamin D3 in IBD Patients on Remicade
NCT03162432Phase 3Unknown
- Sponsor
- Boston Children's Hospital
- Start
- Aug 2017
- Primary completion
- Dec 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vitamin d in inflammatory bowel disease (IBD) and Vitamin D deficiency (VDD), sponsored by Boston Children's Hospital. Primary endpoint: Ability of intervention to maintain 25-OH Vitamin D levels in the 35-80 range at 1 year. Status: unknown.
02
Drugs
vitamin d
03
Conditions
inflammatory bowel disease (IBD)Vitamin D deficiency (VDD)
Beyond the preview
Go deeper on NCT03162432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03162432.